146.31 USD
+0.56 (+0.38%)
146.31 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to TMDX. TMDX was compared to 188 industry peers in the Health Care Equipment & Supplies industry. TMDX has an excellent financial health rating, but there are some minor concerns on its profitability. TMDX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make TMDX suitable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year TMDX was profitable.
TMDX had a positive operating cash flow in the past year.
In the past 5 years TMDX reported 4 times negative net income.
TMDX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 9.71%, TMDX belongs to the best of the industry, outperforming 92.55% of the companies in the same industry.
TMDX has a better Return On Equity (25.88%) than 96.28% of its industry peers.
TMDX has a Return On Invested Capital of 8.72%. This is amongst the best in the industry. TMDX outperforms 87.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.71% | ||
| ROE | 25.88% | ||
| ROIC | 8.72% |
ROA(3y)-4.09%
ROA(5y)-12.79%
ROE(3y)-7.43%
ROE(5y)-23.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TMDX has a Profit Margin of 16.22%. This is amongst the best in the industry. TMDX outperforms 92.55% of its industry peers.
TMDX's Operating Margin of 16.89% is amongst the best of the industry. TMDX outperforms 87.23% of its industry peers.
TMDX has a Gross Margin of 60.28%. This is comparable to the rest of the industry: TMDX outperforms 59.57% of its industry peers.
In the last couple of years the Gross Margin of TMDX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.89% | ||
| PM (TTM) | 16.22% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
TMDX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, TMDX has more shares outstanding
The number of shares outstanding for TMDX has been increased compared to 5 years ago.
TMDX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 6.12 indicates that TMDX is not in any danger for bankruptcy at the moment.
TMDX has a Altman-Z score of 6.12. This is amongst the best in the industry. TMDX outperforms 80.32% of its industry peers.
TMDX has a debt to FCF ratio of 4.27. This is a neutral value as TMDX would need 4.27 years to pay back of all of its debts.
The Debt to FCF ratio of TMDX (4.27) is better than 79.79% of its industry peers.
TMDX has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of TMDX (1.43) is worse than 79.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.27 | ||
| Altman-Z | 6.12 |
ROIC/WACC1.09
WACC8.02%
2.3 Liquidity
TMDX has a Current Ratio of 7.66. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 7.66, TMDX belongs to the best of the industry, outperforming 88.83% of the companies in the same industry.
A Quick Ratio of 7.10 indicates that TMDX has no problem at all paying its short term obligations.
TMDX has a Quick ratio of 7.10. This is amongst the best in the industry. TMDX outperforms 89.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.66 | ||
| Quick Ratio | 7.1 |
3. Growth
3.1 Past
TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 162.77%, which is quite impressive.
The Revenue has grown by 41.20% in the past year. This is a very strong growth!
The Revenue has been growing by 79.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
TMDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.52% yearly.
TMDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.23% yearly.
EPS Next Y162.03%
EPS Next 2Y69.97%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue Next Year39.7%
Revenue Next 2Y29.73%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 59.23, TMDX can be considered very expensive at the moment.
Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than 68.62% of the companies in the same industry.
TMDX is valuated expensively when we compare the Price/Earnings ratio to 26.31, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 50.14, which means the current valuation is very expensive for TMDX.
Based on the Price/Forward Earnings ratio, TMDX is valued a bit cheaper than the industry average as 69.68% of the companies are valued more expensively.
TMDX's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 36.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.23 | ||
| Fwd PE | 50.14 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TMDX is valued a bit cheaper than 69.15% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, TMDX is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.66 | ||
| EV/EBITDA | 41.48 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TMDX's earnings are expected to grow with 53.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.37
PEG (5Y)N/A
EPS Next 2Y69.97%
EPS Next 3Y53.74%
5. Dividend
5.1 Amount
No dividends for TMDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
146.31
+0.56 (+0.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.43%
Inst Owner Change1.45%
Ins Owners2.96%
Ins Owner Change-0.12%
Market Cap5.00B
Revenue(TTM)566.35M
Net Income(TTM)91.86M
Analysts83.16
Price Target146.29 (-0.01%)
Short Float %22.8%
Short Ratio7.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)-2.04%
PT rev (3m)-5.02%
EPS NQ rev (1m)1.89%
EPS NQ rev (3m)3.41%
EPS NY rev (1m)9.81%
EPS NY rev (3m)10%
Revenue NQ rev (1m)0.45%
Revenue NQ rev (3m)0.44%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)-0.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.23 | ||
| Fwd PE | 50.14 | ||
| P/S | 8.83 | ||
| P/FCF | 41.66 | ||
| P/OCF | 28.09 | ||
| P/B | 14.08 | ||
| P/tB | 14.66 | ||
| EV/EBITDA | 41.48 |
EPS(TTM)2.47
EY1.69%
EPS(NY)2.92
Fwd EY1.99%
FCF(TTM)3.51
FCFY2.4%
OCF(TTM)5.21
OCFY3.56%
SpS16.57
BVpS10.39
TBVpS9.98
PEG (NY)0.37
PEG (5Y)N/A
Graham Number24.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.71% | ||
| ROE | 25.88% | ||
| ROCE | 11.04% | ||
| ROIC | 8.72% | ||
| ROICexc | 18.9% | ||
| ROICexgc | 19.58% | ||
| OM | 16.89% | ||
| PM (TTM) | 16.22% | ||
| GM | 60.28% | ||
| FCFM | 21.19% |
ROA(3y)-4.09%
ROA(5y)-12.79%
ROE(3y)-7.43%
ROE(5y)-23.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.27 | ||
| Debt/EBITDA | 4.17 | ||
| Cap/Depr | 223.08% | ||
| Cap/Sales | 10.24% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.33% | ||
| Profit Quality | 130.63% | ||
| Current Ratio | 7.66 | ||
| Quick Ratio | 7.1 | ||
| Altman-Z | 6.12 |
F-Score7
WACC8.02%
ROIC/WACC1.09
Cap/Depr(3y)950.14%
Cap/Depr(5y)614.59%
Cap/Sales(3y)35.03%
Cap/Sales(5y)23.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y162.03%
EPS Next 2Y69.97%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.7%
Revenue Next 2Y29.73%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
EBIT growth 1Y204.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year292.7%
EBIT Next 3Y89.1%
EBIT Next 5Y68.49%
FCF growth 1Y186.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y801.62%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
What is the valuation status for TMDX stock?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for TMDX stock?
The Price/Earnings (PE) ratio for TRANSMEDICS GROUP INC (TMDX) is 59.23 and the Price/Book (PB) ratio is 14.08.
What is the financial health of TRANSMEDICS GROUP INC (TMDX) stock?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 6 / 10.